Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Epothilone D · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Phase I - Epothilone D Dose Escalation | EXPERIMENTAL | - |
| Phase II - Epothilone D Maximum Tolerated Dose | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Epothilone D | DRUG | ≤100 mg/m\^2 intravenously (iv) on days 1, 8 and 15 once every 4 weeks |
| Herceptin | DRUG | 4mg/kg iv loading dose, followed by 2mg/kg iv weekly |
Inclusion Criteria: * women \>=18 years; * locally advanced or metastatic breast cancer; * HER-2 overexpression (FISH + or IHC 3+); * \>=1 measurable lesion; * up to one prior anthracycline-based chemotherapy regimen in a metastatic setting. Exclusion Criteria: * pre-existing neuropathy \>=grade ...
Top 20 of 92 competitors
Epothilone D is an investigational small molecule being studied for the treatment of breast cancer, specifically in patients with HER-2 positive advanced or metastatic breast cancer. It is being developed by Roche Holding AG and is currently in Phase 1 clinical development.
Epothilone D is a small molecule that targets microtubules, a component of the cell's cytoskeleton. By stabilizing microtubules, it disrupts cell division, which can lead to cancer cell death. This mechanism is similar to that of taxanes, but Epothilone D is a distinct chemical entity.
Epothilone D is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded on the OTC market under the ticker symbol RHHBY. The drug is currently in Phase 1 clinical trials for breast cancer.
Epothilone D is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in a Phase 1 trial for HER-2 positive advanced or metastatic breast cancer, which has been completed.
Epothilone D has been studied in one clinical trial, identified by the NCT number NCT00337649. This was a Phase 1 study of Epothilone D in combination with Herceptin (trastuzumab) in patients with HER-2 positive advanced or metastatic breast cancer. The trial was completed and enrolled 27 female participants in Spain.
No, Epothilone D is not the same as Ixabepilone. While both are epothilone derivatives that stabilize microtubules, they are distinct chemical compounds. Epothilone D is being developed by Roche, whereas Ixabepilone is a different drug that has been approved for breast cancer under the brand name Ixempra.